Is cure possible now for myeloma patients?
Professor Sagar Lonial (Atlanta, USA) and Professor Philippe Moreau (Nantes, France) discuss whether patients are being cured now and what the future holds.
Professor Sagar Lonial (Atlanta, USA) and Professor Philippe Moreau (Nantes, France) discuss whether patients are being cured now and what the future holds.
Article written by Tom Collins. Interview by Esther Drain.
Pomalidomide with bortezomib and dexamethasone is one of the best options for multiple myeloma patients who have relapsed while on lenalidomide, but other data are in the offing that could provide even more options, said Professor Philippe Moreau, head of the haematology department at University Hospital in Nantes, France.
Article written by Tom Collins. Interview by Esther Drain. Meletios Dimopoulos, MD, professor and chairman of clinical therapeutics at the University of Athens and a long-time expert in… read more.
Article written by Tom Collins. Interview by Esther Drain In a debate about whether autologous stem cell transplant (ASCT) is still right for all transplant eligible MM patients,… read more.
Pomalidomide with bortezomib and dexamethasone is one of the best options for multiple myeloma patients who have relapsed while on lenalidomide, but other data are in the offing… read more.
Professor Philippe Moreau (Nantes, France) and Professor Paul Richardson (Boston, USA) give their opinion on sequencing in myeloma and options at relapse and Dr Rakesh Popat (London, UK) highlights the real life management… read more.
In the ‘Great Debates in MM’ session Professor Paul Richardson (Boston, USA) argued the pros and cons of RVd vs KRd in the frontline. Written by Esther Drain
Many newly diagnosed patients receive multiple myeloma treatment for more than 12 months, according to data collected from treatment centers around the world, showing that the shift away… read more.
Progression-free survival (PFS) and overall survival (OS) were improved similarly with maintenance therapy with lenalidomide or bortezomib in two studies presented at the International Myeloma Workshop. Written by… read more.
Preliminary results from a real-world study show that patients at an older age with a high comorbidity burden had their normal activities uninterrupted when they switched to the… read more.
“The genome can be thought of as the hardware driving a cell whereas the epigenome is more like the software – it is dynamic and erasable”, said Professor Ari… read more.
Prof Stephen Ansell (Rochester, USA) discusses how the new cellular technologies are being integrated into standard practice.Written by Esther Drain.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.